U.S. stock night market opening fluctuations: Ramaco - CL fell 8.37% in night trading; IBM rose 7.29% in night trading

U.S. Stock Night Market Opening Movements Ramaco - CL fell 8.37% in the night market. Based on recent news, On January 27, analyst Ben Kallo maintained a buy rating on Ramaco Resources and set a target price of $40. This move shows market confidence in the company, despite the stock price decline in the night market. On January 26, a report from Baird indicated that federal government investments in critical mineral companies may continue, with Ramaco Resources listed as a "bullish new stock." The government's investment in USA Rare Earth suggests that Ramaco is expected to benefit from the establishment of a domestic rare earth and magnet supply chain. On January 26, the Department of Defense reached a preliminary investment agreement with MP Materials, and other rare earth stocks also rose. MP Materials increased by 5.7%, while Ramaco Resources rose by 8.2%. The rare earth industry has performed strongly recently, with clear policy support. IBM rose 7.29% in the night market. Based on recent key news: On January 28, IBM announced its fourth-quarter financial report, with revenue increasing by 12% year-on-year to $19.69 billion, exceeding analyst expectations of $19.2 billion. The software business grew by 14% to $9.03 billion, driving the stock price up over 7% in after-hours trading. Source: Zhitong Finance On January 28, IBM announced a revenue growth forecast of over 5% for 2026, with free cash flow expected to increase by $1 billion, enhancing market confidence. Source: Bloomberg On January 28, IBM's board approved a quarterly dividend of $1.68 per share, further attracting investor attention. Source: Benzinga The overall performance of the technology sector has been strong, with significant capital inflows. Top Gainers in the U.S. Stock Night Market Serina Therapeutics rose 31.99% in the night market. Based on recent key news: On January 28, Serina Therapeutics announced that its drug SER-252 for the treatment of advanced Parkinson's disease received FDA IND application approval. This news significantly boosted the company's stock price, reflecting market optimism about the drug's potential commercial success. Source: Reuters On January 28, the company released relevant information through the EDGAR system, emphasizing the risks and regulatory impacts of drug development. Despite the risks, investors remain optimistic about future positive developments. Source: EDGAR On January 28, the company discussed the risks of drug development and competitive dynamics in its annual report; nevertheless, the market expressed confidence in its innovation capabilities and future potential. Source: Company Announcement The U.S. biotechnology sector has performed strongly recently CL Workshop rose 16.82% in after-hours trading, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Tanzania Royal Exploration rose 15.03% in after-hours trading. Based on recent key news: On January 27, TRX Gold Corporation was rated as a buy by analysts, despite better investment options. Analysts believe TRX Gold has good investment opportunities in the gold industry, but other more attractive stocks in the market have led to price fluctuations. On January 26, TRX Gold acquired the Casa Berardi mine, enhancing its production capacity and exploration potential. The transaction is expected to be completed in the first quarter of 2026, supporting the company's diversification and driving up the stock price. On January 28, TRX Gold enhanced shareholder value through a stock repurchase program. The company's internal financing growth and record gold prices provided favorable conditions, resulting in a stock price increase. The gold industry has performed strongly recently, with significant capital inflows